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Abstract
Background: Ambulatory electrocardiographic (ECG) monitoring is the standard to screen for high-risk arrhythmias.
We evaluated the clinical utility of a novel, leadless electrode, single-patient-use ECG monitor that stores up to
14 days of a continuous recording to measure the burden and timing of potentially high-risk arrhythmias.
Methods: We examined data from 122,815 long term continuous ambulatory monitors (iRhythm ZIO® Service, San
Francisco) prescribed from 2011 to 2013 and categorized potentially high-risk arrhythmias into two types: (1) ventricular
arrhythmias including non-sustained and sustained ventricular tachycardia and (2) bradyarrhythmias including sinus
pauses >3 s, atrial fibrillation pauses >5 s, and high-grade heart block (Mobitz Type II or third-degree heart block).
Results: Of 122,815 ZIO® recordings, median wear time was 9.9 (IQR 6.8–13.8) days and median analyzable time was
9.1 (IQR 6.4–13.1) days. There were 22,443 (18.3 %) with at least one episode of non-sustained ventricular tachycardia
(NSVT), 238 (0.2 %) with sustained VT, 1766 (1.4 %) with a sinus pause >3 s (SP), 520 (0.4 %) with a pause during atrial
fibrillation >5 s (AFP), and 1486 (1.2 %) with high-grade heart block (HGHB). Median time to first arrhythmia was 74 h
(IQR 26–149 h) for NSVT, 22 h (IQR 5–73 h) for sustained VT, 22 h (IQR 7–64 h) for SP, 31 h (IQR 11–82 h) for AFP, and
40 h (SD 10–118 h) for HGHB.
Conclusions: A significant percentage of potentially high-risk arrhythmias are not identified within 48-h of ambulatory
ECG monitoring. Longer-term continuous ambulatory ECG monitoring provides incremental detection of these
potentially clinically relevant arrhythmic events.
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Background
Ambulatory electrocardiographic (ECG) monitoring is
the standard of care to screen symptomatic outpatient
adults for high-risk ventricular and atrial arrhythmias
[1–3]. However, there is marked variation in the techno-
logical features and patient compliance among different
ECG monitoring systems [4, 5]. Traditional 24-h monitoring
devices (i.e., Holter monitors) often do not detect symp-
tomatic or clinically meaningful arrhythmias [6, 7].
Recent technological advances have allowed for higher
fidelity recording and larger storage capacities that are
able to capture full disclosure ECG recordings beyond
the traditional 24- or 48-h monitoring periods. Further-
more, innovative device designs aim to increase patient
convenience and patient compliance. Emerging evidence
suggests that longer wear times yield greater arrhythmia
detection in selected at-risk patients that could impact
clinical decision-making and outcomes [8]. Although
there has been very limited evaluation of this approach
outside of detecting the presence of atrial fibrillation,
longer monitoring periods are emerging as a new stand-
ard of care for selected patients.
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To understand the applicability in day-to-day clinical
practice, we evaluated contemporary results from a
novel, long-term ambulatory ECG monitoring system to
measure the burden and timing of potentially high-risk
arrhythmias, including ventricular tachycardia, high-grade
heart block and clinically significant pauses in atrioven-
tricular conduction.
Methods
Data and study population
We analyzed data for all the ZIO® Service long-term
continuous ambulatory ECG monitors (ZIO® Service,
iRhythm Technologies, Inc., San Francisco, California)
that were prescribed from November 2011 to December
2013 (N = 128,401). The ZIO® Patch is a lightweight,
lead-wire free, single-patient-use ECG monitor that ad-
heres to the left upper chest and records and stores up
to 14 days of continuous, beat-to-beat ECG. Patients
have the option of pressing a trigger button on the de-
vice and filling out a log to document symptomatic
events during their wear duration, which allows for
symptom-rhythm correlation in the ECG report. After a
patient completes their 14-day recording, the ZIO® Patch
is removed from the chest and mailed to iRhythm Tech-
nologies, Inc., where the up to 14-day single-channel re-
cording is analyzed using a combination of proprietary
algorithms and review by Certified Cardiac Technicians
(CCT). The findings are then reported to the ordering
physician in a report that includes information on several
standard arrhythmias, including atrial fibrillation and flut-
ter, ventricular tachycardia, supraventricular tachycardia,
atrioventricular pauses, heart block, atrial and ventricular
ectopic beats, and other identified arrhythmias. All com-
ponents of the device are recycled after data downloading.
Further details on the ZIO® Service and its analytic algo-
rithms have been described previously [5, 9].
We applied standard quality control techniques to as-
semble a cleaned, analytic dataset of basic patient infor-
mation and detailed information on detected arrhythmias.
This included removing outliers that contained likely erro-
neous data, including records with heart rates >300 beats
or <20 per minute, along with excluding patients <18 years
old, records with start times outside our study dates, and
records with wear-time or analyzable-time of less than
24 h. Analyzable time was calculated as the amount of
time that the ECG patch was recording (enrollment
period) minus the amount of time of unanalyzable ECG
signal due to artifact.
Outcomes
We categorized potentially high-risk arrhythmias into
two types: (1) ventricular arrhythmias, including non-
sustained and sustained ventricular tachycardia; and (2)
bradyarrhythmias including sinus pauses >3 s, atrial
fibrillation pauses >5 s, and high grade heart block in-
cluding Mobitz Type II or third-degree heart block. Sus-
tained ventricular tachycardia (VT) included VT that
lasted greater than 30 s. Mobitz II heart block and third
degree heart block were identified by the manufacturer
according to their FDA-cleared algorithms and 100 %
data curation and quality review by CCT’s trained in ad-
vanced arrhythmia detection. Symptomatic pauses were
defined as a pause (greater than 3 s for sinus rhythm
and greater than 5 s for those in atrial fibrillation) that
occurred within 45 s of a patient trigger.
Statistical analysis
All analyses were performed at the Kaiser Permanente
Northern California Division of Research using SAS stat-
istical software, version 9.3 (Cary, N.C.). Continuous var-
iables were reported as means with standard deviations
and categorical variables as frequencies and proportions.
We calculated the proportion and associated 95 % confi-
dence interval of patients with each arrhythmia overall
and the cumulative yield per additional day of monitoring.
We used chi-squared tests to compare the proportion of
high-risk arrhythmias detected at 1-, 2-, and 7-days versus
14-days.
A research exemption was obtained from the institu-
tional review board of the Kaiser Foundation Research
Institute given that the analyses were completed on a
fully de-identified dataset provided by iRhythm Tech-
nologies, Inc, and therefore no formal ethics approval
was required for this study.
Results
Study sample and distribution of wear and analyzable
time
During the study period, we identified 122,815 eligible
ZIO® Patch records contributed by 122,454 unique
patients (Fig. 1). The overall mean wear time was
9.6 ± 4.0 days, and more than 25 % of the recorders were
worn for at least 13.8 days. Analyzable time was similar,
with 25 % of recorders containing greater than 13 days of
analyzable time.
Cumulative detection of potentially high-risk arrhythmias
Of the 122,815 eligible records, there were 22,443 (18 %)
with nonsustained VT, 238 (0.2 %) with sustained VT,
1766 (1.4 %) with sinus pauses >3 s, 521 (0.4 %) with AF
pauses >5 s, 249 (0.2 %) with symptomatic pauses and
1468 (0.4 %) with high-grade heart block (Table 1).
Overall, ventricular arrhythmias were more prevalent
than bradyarrhythmias, although this was driven by the
large burden of episodes of nonsustained VT.
More than half (53 %) of the recorders were worn by
women; but for nearly all arrhythmias except symptom-
atic pauses, there were more detected arrhythmias
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among men than women. Although nearly half (49.8 %)
of the analyzed patients were for patients aged less than
65 years old, the majority of all detected arrhythmias
were among patients aged 65 years or older.
Timing of detection of potentially high-risk arrhythmias
For the detection of ventricular arrhythmias, there was a
marked increase in arrhythmia detection over the course
of the 14-day monitors (Fig. 2). For sustained VT, only
52.5 % of the total identified arrhythmias were identified
at 24 h, and approximately two-thirds (65.5 %) were
identified by 48 h. Most arrhythmias were identified by
7 days (92.9 %), but the additional 7 days of monitoring
between 7 and 14 days yielded an additional 7.1 % of
these potentially lethal arrhythmias. A similar trend was
seen for the more common non-sustained VT, with 23.4,
38.0, and 79.4 % of all non-sustained VT being identified
by 1, 2, and 7 days respectively. These trends were
Fig. 1 Cohort assembly














N = 122,815 N = 22,443 N = 238 N = 1,766 N = 521 N = 249 N = 1,468
Age, years, N (%)
< 65 61,170 (49.8) 7,787 (34.7) 102 (42.9) 497 (28.1) 88 (16.9) 60 (24.1) 481 (32.8)
65–79 42,469 (34.6) 9,596 (42.8) 102 (42.9) 735 (41.6) 272 (52.2) 133 (53.4) 582 (39.7)
≥ 80 19,176 (15.6) 5,060 (22.6) 34 (14.3) 534 (30.2) 161 (30.9) 56 (22.5) 405 (27.6)
Women, N (%) 65,081 (53.0) 8,316 (37.1) 59 (24.8) 698 (39.5) 238 (45.7) 131 (52.6) 571 (38.9)
Wear Days
Mean (Standard Deviation) 9.6 (4.0) 10.8 (3.5) 10.7 (3.4) 10.7 (3.7) 11.1 (3.4) 10.9 (3.5) 10.4 (3.7)
Median (IQR) 9.9 (6.8–13.8) 12.9 (7.1–13.9) 12.1 (7.1–13.9) 12.9 (7.0–14.0) 13.0 (7.3–14.0) 12.9 (7.1–14.0) 12.1 (7.0–13.9)
Analyzable Days
Mean (Standard Deviation) 9.2 (3.9) 10.4 (3.5) 10.1 (3.4) 10.2 (3.7) 10.5 (3.3) 10.3 (3.4) 9.9 (3.7)
Median (IQR) 9.1 (6.4–13.1) 11.8 (7.0–13.6) 11.3 (6.9–13.4) 11.8 (6.9–13.6) 12.1 (7.1–13.6) 11.7 (7.0–13.5) 10.9 (6.8–13.5)
aIncluded Mobitz II heart block and third-degree heart block
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Fig. 2 Cumulative Yield of Sustained and Non-sustained Ventricular Tachycardia. Data are shown for the overall population of patients with the
arrhythmia and stratified by age and gender
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similar for both men and women and across all age
ranges, although sustained VT was detected earlier
among very elderly patients (aged 80 years and older).
The detection of potentially high risk bradyarrhyth-
mias was similarly enhanced with longer monitoring pe-
riods (Fig. 3). The difference in bradyarrhythmia yield
between 1-, 2- and 7-days was substantial. For the most
common bradyarrhythmia, sinus pauses >3 s (N = 1766),
31.7 % of the total detected arrhythmias were found
within 1 day, 46.6 % within 2 days, and 83.1 % within
3 days of monitoring. Similar trends were observed for the
other bradyarrhythmias, and these trends were consistent
for both genders and across age categories. The diagnostic
yields at 2 days versus 7 days for ventricular arrhythmias
and bradyarrhythmias were significantly different from
each other in the overall populations (P < 0.01).
Discussion
Within a very large, contemporary study analyzing
nearly 123,000 long-term continuous ambulatory cardiac
monitors that were prescribed between 2011 and 2013,
we found a moderate burden of potentially high-risk ar-
rhythmias, including both ventricular arrhythmias and
bradyarrhythmias. Patient compliance with extended
monitoring was high, with at least 25 % of patients
achieving greater than 13 days of continuous monitor-
ing. For all arrhythmias examined, longer monitoring
times significantly increased the yield of detected ar-
rhythmias. While the gains in arrhythmia yield were par-
ticularly marked in the first 7 days of monitoring, it is
notable that the gains continued to increase from days 7
to 14. The relatively high wear and analyzable time for
the longer term continuous monitors suggests that out-
patient ECG monitoring using this approach is feasible
and can have significant yield of clinically important ar-
rhythmias beyond atrial fibrillation. Our study examined
a more recent time period than prior investigations of
long-term continuous monitors [5, 9] and suggests that
changes in the device technology and accumulated oper-
ator experience may have resulted in improved patient
compliance.
Prior research suggests that traditional 24-h Holter
monitoring is not sufficiently long enough to detect
many types of arrhythmias [10–13], and recent evidence
has demonstrated that longer monitoring may be useful
to detect arrhythmias in high-risk patient populations,
such as those with a recent history of cryptogenic ische-
mic stroke [8, 14], although the majority of these studies
have focused primarily on finding atrial fibrillation. For
example, in a registry of 239 patients who wore 30-day
loop recorders after discharge for cryptogenic ischemic
stroke, researchers found that 24 % of all detected cases
of occult atrial fibrillation were found in the final 10 days
of 30-day monitoring (i.e., between days 20 and 30) [14].
Similarly, in a larger controlled trial of a similar patient
population where 24-h Holter monitoring was compared
to 30-day monitoring, 17 % of all cases of atrial fibrilla-
tion were detected in the final week of monitoring [8].
Although conventional wisdom suggests that longer
monitoring may be useful for detecting rarer, potentially
high-risk arrhythmias, such as ventricular arrhythmias
and bradyarrhythmias, there is little empirical evidence
on the impact and diagnostic yield of longer continuous
monitoring for other clinically meaningful arrhythmias
outside of atrial fibrillation. One advantage to the stud-
ied technology compared to typical 24- or 48-h Holter
monitor systems is its longer continuous wear time up
to 14 days, as well as its application without any long
wires attached to distant electrodes. For longer monitor-
ing periods, loop or event recorders have typically been
the preferred technology, with the main disadvantage
being that recordings are only stored if they meet pre-
defined algorithms or for symptomatic triggers. A
post-hoc investigation of the patient’s rhythm pre-or
post-event cannot be done. Implantable loop recorders
are occasionally used for very rare arrhythmia events,
but these have the same limitations as loop and event
monitors and also require a small surgical procedure to
implant the device with its attendant risks.
For ventricular arrhythmias, we found that although
the majority of arrhythmias are identified in the first
7 days, a significant proportion of arrhythmias were still
detected in the 7 to 14-day monitoring window. This
was more pronounced for non-sustained VT than sus-
tained VT, with more than 20 % of non-sustained VT
being identified in the 7–14 day window. Although we
did not have detailed clinical characteristics for our patient
population, in high-risk patients, such as those with car-
diomyopathy, non-sustained VT can be a high risk marker
that may warrant a change in treatment such as the con-
sideration of an implantable cardioverter-defibrillator in
certain patient populations (i.e., hypertrophic cardiomyop-
athy). Depending upon the clinical circumstances, both
nonsustained and sustained VT often support the need
for further diagnostic testing, such as the evaluation for
structural heart disease or for cardiac ischemia. Similarly,
although potentially high-risk bradyarrhythmias were less
common, if they are not appropriately identified and
treated, patients may suffer significant morbidity and ex-
cess mortality. The consideration of therapeutic interven-
tions such as permanent pacemaker implantation is
recommended by the joint American College of Cardi-
ology, American Heart Association, and Heart Rhythm
Society guidelines for the high-risk bradyarrhythmias eval-
uated in our study [15].
Our study had certain limitations. We did not have
data on any changes in clinical management or patient
outcomes following monitoring, so we were unable to
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Fig. 3 Cumulative yield of pauses and high grade heart block. Data are shown for the overall population of patients with the arrhythmia and
stratified by age and gender. AF = atrial fibrillation
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delineate the direct clinical impact from the detection of
arrhythmias found from the monitors in our study. We
did not have information on all symptomatic triggers,
and thus did not analyze the proportion of all symptom-
atic triggers that correlate to true arrhythmias. Patient
information was limited to demographic characteristics,
and data were unavailable on patients’ comorbidities,
which could potentially help further risk stratify patients
and allow for predictive modeling to help identify those
most at-risk for high-risk arrhythmias. In addition, some
bradyarrhythmias, such as asymptomatic sinus and AF
pauses, may occur nocturnally in normal subjects. Fur-
ther, we did not validate the data on the clinical indica-
tion for the ordered monitors, and differences among
providers’ thresholds for ordering the monitors could
have an impact on patient selection and arrhythmia
yield. Finally, while average wear time was high, at least
a quarter of patients wore the device for less than 7 days
(25th percentile of 6.8 days), thus artificially reducing
the yield of detected arrhythmias from 7 to 14 days.
Thus, the actual yield of detected arrhythmias from days
7 to 14 or monitoring may be even higher than we
observed.
Conclusion
In sum, our study suggests that longer term monitoring
up to 14 days resulted in high patient compliance, and
greater detection of high-risk arrhythmias than 24- or
48-h monitoring strategies. We observed similar findings
across gender and age subgroups. Although the bulk of
arrhythmias were detected within the first 7 days, longer-
term monitoring between 7 and 14 days yielded a signifi-
cant number of likely clinically meaningful, potentially
high-risk arrhythmias. Future research should examine
the clinical utility of improved high-risk arrhythmia detec-
tion in targeted patient groups and its impact on patient
management and associated clinical outcomes.
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